HALO | Brokers Set Expectations for Halozyme Therapeutics, Inc.’s Q4 2020 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc.(NASDAQ:HALO) – Equities research analysts at Jefferies Financial Group increased their Q4 2020 EPS estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Monday, November 2nd.Jefferies Financial Group analyst E.Yang now expects that the biopharmaceutical company will post earnings of $0.59 per share […]Daily Political

HALO | Equities Analysts Issue Forecasts for Halozyme Therapeutics, Inc.’s FY2020 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc.(NASDAQ:HALO) – Equities researchers at Cantor Fitzgerald raised their FY2020 EPS estimates for shares of Halozyme Therapeutics in a note issued to investors on Tuesday, November 3rd.Cantor Fitzgerald analyst C.Duncan now forecasts that the biopharmaceutical company will earn $0.82 per share for the year, up from their prior forecast of […]Daily Political

HALO | Halozyme Therapeutics (NASDAQ:HALO) Releases Earnings Results, Beats Expectations By $0.05 EPS

Halozyme Therapeutics (NASDAQ:HALO) issued its quarterly earnings data on Monday.The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05, MarketWatch Earnings reports.Halozyme Therapeutics had a negative return on equity of 31.71% and a negative net margin of 22.00%.The business had […]The Olympia Report